Why did the FDA decline Novocure’s Optune Mya device for lung cancer that spread to the brain?
On Nov. 9, 2026 the FDA declined to approve Novocure’s Optune Mya for lung cancer that has spread to the brain. Per the company, the agency questioned clinical benefit and raised no safety concerns; Novocure plans to meet the FDA. Factual, no hype.
The news, without hype: on Monday, Nov. 9, 2026, the FDA declined to approve Novocure’s Optune Mya device for lung cancer that has spread to the brain. According to the company, the agency questioned whether the device delivers enough clinical benefit for this use, and raised no safety concerns.
Novocure says it plans to meet with the FDA to discuss the path forward.What it means: a decline like this is a “not yet, on this evidence” — not a finding that the device is dangerous, and not an approval, either. Anyone affected should talk with their own oncologist rather than read a regulatory decision as personal medical news.
Ask AI about this tip
Send this tip to your favorite AI assistant for a plain-language walkthrough, follow-up questions, or help applying it to your device.